Diagnostic and therapeutic advances in growth hormone insensitivity.
Diagnostic and therapeutic advances in growth hormone insensitivity (GHI) have occurred principally in two areas: the molecular characterization of patients with GHI and treatment with recombinant human insulin like growth factor-I (IGF-I). This article discusses the current status of molecular diagnosis across the spectrum of the disorder. Treatment with recombinant human IGF-I in classical cases is summarized, and potential new targets for treatment are discussed together with the potential for therapy using the newly developed compound recombinant human IGF-I/IGF binding protein-3.
David
Alessia
A
Molecular Endocrinology Centre, William Harvey Research Institute, St. Bartholomew's Hospital, London, UK.
Metherell
Louise A
LA
Clark
Adrian J L
AJ
Camacho-Hübner
Cecilia
C
Savage
Martin O
MO
D004359:Drug Therapy, Combination; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000627:therapeutic use; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use; D046150:Laron Syndrome / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics; D009154:Mutation; D011986:Receptors, Somatotropin / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000627:therapeutic use
D018972:Insulin-Like Growth Factor Binding Protein 3; D011986:Receptors, Somatotropin; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I